Effect of Protease-Activated Receptor-2-Activating Peptide on Guinea Pig Airway Resistance and Isolated Tracheal Strips.

PURPOSE: Protease-activated receptors (PARs) are a family of G-protein-coupled receptors distributed in a number of tissues. PAR-2 is expressed on airway epithelium and smooth muscles and overexpressed under pathological conditions, such as asthma and chronic obstructive pulmonary disease. However, the role of PAR-2 in airways has not yet been defined. In this study, we investigated the role of PAR-2-activating peptide (SLIGRL) on histamine-induced bronchoconstriction and the mechanisms underlying the bronchoprotective effect both in vivo and in vitro.
MATERIALS AND METHODS: The effect of SLIGRL was tested in vivo using histamine-induced bronchoconstriction in the guinea pig and in vitro using isolated tracheal spiral strips.
RESULTS: In vivo pretreatment with SLIGRL significantly reduced the histamine-induced increased bronchoconstriction. Neither propranolol nor vagotomy abolished the inhibitory effect of SLIGRL. Furthermore, indomethacin or glibenclamide did not antagonize the inhibitory response to SLIGRL. In isolated tracheal spiral strips in vitro, SLIGRL did not affect the contractile response to acetylcholine or potassium chloride; however, histamine-induced contraction was inhibited in a dose-dependent manner.
CONCLUSION: Our data demonstrate the protective effect of SLIGRL in airways; however, this effect appears to be mediated independently of prostanoids, nitric oxide, circulating adrenaline, ATP-sensitive K + channels, and vagal stimulation. Copyright:

INTRODUCTION

Protease-activated receptors (PARs) are a family of G-protein­coupled receptors activated by site-specific proteolytic cleavage of a “tethered ligand” or PAR-activating peptide (PAR-AP).[1] Four members of this family have been identified to date, and expression has been detected in many different cell types including immune cells, platelets, endothelial cells, and smooth muscle cells.[2] PARs function in a variety of physiological and pathological processes such as hemostasis, thrombosis, embryonic development, wound healing, inflammation, and cancer progression.[3]

While PAR-1, 3, and 4 are activated by thrombin, PAR-2 is activated by serine proteases such as trypsin and tryptase,[456] an enzyme released after mast cell degranulation and considered to play an important role in airway inflammation and hyperresponsiveness.[7] Activation of PAR-1 and PAR-2 leads to an endothelium-dependent relaxation of a large array of arterial blood vessels[8] and contraction of gastric smooth muscle.[9] Under physiological conditions, PAR-2 is expressed on several human tissues such as the gastrointestinal tract, pancreas, kidney, liver, lung, ovary, and eye[1011] and also under pathological conditions such as asthma and chronic obstructive pulmonary disease.[12] PAR-2 is also markedly upregulated after exposure to pro-inflammatory stimuli or cytokines,[13] which have been shown to play a critical role in chronic airway diseases. Moreover, human bronchial smooth muscle cells isolated from asthmatic patients express increased PAR-2 levels, which may contribute to airway hyperresponsiveness.[14]

Cicala et al.[15] showed that in vivo, inflammatory stimuli, such as bacterial lipopolysaccharide (LPS), upregulate PAR-2 expression on vascular endothelium, and smooth muscle cells, correlating with an increase in the hypotensive effect of the synthetic PAR-2-AP. These data suggest a pro-inflammatory effect of PAR-2 activation. In contrast, there is also evidence for a protective anti-inflammatory effect following activation of PAR-2. PAR-2 is expressed in the human lung[1116] and in the airways, activation of PAR-2 causes an epithelium-dependent relaxation of mouse-isolated bronchi that correlates with PAR-2 immunoreactivity in the cytoplasmic regions of airway epithelial cells[17] and of mouse tracheal rings.[18] In vivo, PAR-2 has been shown to protect against 5HT-induced bronchoconstriction in the rats.[17] Furthermore, bronchi from LPS-treated rats showed an increased relaxant response to PAR-2-AP in vitro.[19] In contrast, PAR-2 activation was shown to induced to a sensory neuropeptide-dependent bronchoconstrictor response.[20] These conflicting data make the role of PAR-2-AP in airway resistance unclear; therefore, in this study, we investigated the role of PAR-2 in histamine-induced bronchoconstriction in the guinea pig as well as the signaling mechanism involved in the bronchoprotective effect of PAR-2 receptor activation in vivo and in vitro.

MATERIALS AND METHODS

Animals

Male guinea pigs (300–350 g) were obtained from the animal house of our University. Animal were maintained under standard conditions at a temperature of 25°C ± 2°C with free access to a standard laboratory diet and water.

Drugs

PAR-2-AP (SLIGRL) (MW: 656.83 g/mol) and a control peptide with a scrambled sequence (LSIGRL) (MW: 656.83) were kindly supplied as a white powder by the Immunopharmacology Department at Southampton General Hospital (UK). Histamine acid phosphate, indomethacin, L-NAME, propranolol, glibenclamide, acetylcholine (ACh), and potassium chloride (KCl) were purchased from Sigma Chemical Co (St. Louis, MO USA). Drugs were dissolved in phosphate-buffered saline (PBS), except ACh and KCl, which were dissolved in water.

In vivo experiments

The airway resistance of the anesthetized guinea pigs was measured according to the method described by Bertrand et al.[21] Male guinea pigs (weight, 300–400 g) were anesthetized with sodium pentobarbital (45 mg/kg, intraperitoneally). The trachea was exposed, and animals were ventilated artificially through a tracheal cannula, which was connected to a respirator (Miniature Ideal pump Assembly 230 v., Bioscience, UK). The frequency of respiration was 60 breaths/min and the pump was adjusted to provide a volume of air at a frequency sufficient to abolish spontaneous respiration. The volume of the expired air was measured by connecting one end of a piece of airtight rubber tube to the tracheal cannula, while the other end was connected to a Harvard pressure module 275. The Harvard Chart Mover (mode L 480) was used to record changes in the air outflow, which is the index for the degree of airway resistance. The right femoral vein was cannulated for intravenous drug administration. Animals were allowed a 20-min stabilization period before each experiment.

Experimental protocol

The guinea pigs were randomly allocated to seven groups (G1–G7; n = 5 per group). On the basis of preliminary studies of the effects of different doses of histamine on airway responsiveness, we selected the submaximal dose of 10 μg/kg for evaluating the effects of PAR-2-AP. Five minutes after histamine treatment, scrambled peptide (LSIGRL, 1 mg/kg i.v) (G1) or the PAR-2-AP (SLIGRL, 1 mg/kg i.v) (G2) was administered. Histamine was readministered 1, 5, and 10 min later and the response compared to that obtained before administration of the peptides.[22] Intravenous injection (1 ml/kg) of (PBS) as a control was shown to have no effect on the baseline airway resistance. In Group G3, the guinea pigs were pretreated with propranolol (1 mg/kg i.v)[23] 15 min before the administration of histamine and the effect of PAR-2-AP was then evaluated to rule out the possibility that the effect of PAR-2-AP was due to the adrenergic system activation. In Group G4, the guinea pigs were vagotomized by excision of both the vagal nerves in the neck region[24] before the effect of PAR-2-AP on histamine-induced bronchoconstriction was investigated. In Group G5, the guinea pigs were pretreated with indomethacin (5 mg/kg i.p)[25] 30 min before the administration of histamine and the effect of PAR-2-AP was then evaluated to investigate the role of endogenous prostaglandins.

In Group G6, the guinea pigs were pretreated with L-NAME (30 mg/kg i.v)[22] 15 min before the administration of histamine and the effect of PAR-2-AP was then evaluated to investigate whether nitric was involved in PAR-2-AP effect. In Group G7, the guinea pigs were pretreated with glibenclamide (30 mg/kg i.v)[26] 35 min before the administration of histamine and the effect of PAR-2-AP was then evaluated to investigate the role of ATP-sensitive potassium channels.

In vitro experiments

Tracheal responsiveness experiments were carried out using isolated spiral strips of the guinea pig trachea using the method described by Patterson.[27] The animals were anesthetized by intraperitoneal injection of pentobarbital (100 mg/kg) before the trachea was dissected to remove adhering tissues and cut spirally. The strip was then mounted in 10-ml organ baths containing a modified Krebs–Henseleit solution (118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl, 0.5 mM MgCl2, 25 mM NaHCO3, 1 mM NaHPO4, and 11.1 mM glucose) maintained at 37°C and oxygenated with a mixture of 95% O2 and 5% CO.2. The preparations were allowed to equilibrate for a period of 1 h, during which they were washed at 15 min intervals. An optimal tension of 1 g was applied to tissues fixed to the base of the organ bath. The responses of the tracheal strips to ACh, KCl, and histamine were recorded using an isotonic-sideway writing lever.

The responses of the tracheal strips to previously determined submaximal contraction responses to histamine (4 μg/ml), ACh (4 µg/ml), and KCl (0.2 mg/ml) were recorded in the presence of SLIGRL (10 µM).[20] The effects of different concentrations of SLIGRL (1, 5, and 10 µM) on histamine-induced contraction was also investigated.

Statistical analysis

All data represent the mean ± standard deviation. Differences between two groups were analyzed using Student's t-test. P < 0.05 was considered to indicate statistical significance.[28]

RESULTS

Effect of SLIGRL on airway resistance in vivo

Intravenous administration of histamine at a dose of 10 μg/kg increased baseline airway resistance by a mean of 33.49% ± 2.25%. The control peptide LISGRL had no effect on the histamine-induced increase in baseline resistance [Figure 1 and Supplement 1].

Figure 1

Effect of LS1GRL on histamine-induced bronchoconstriction

However, the pretreatment of animals with SLIGRL (1 mg/kg, i.v) 1 min before histamine challenge produced a significant reduction in histamine-induced airway resistance by 43.94% ± 1.12%) after 1 min (n = 5; P < 0.05) and by 28.55% ± 3.04% after 5 min (n = 5; P < 0.05), while a reduction of only 1.49% ± 0.02% was observed after 10 min [Figure 2 and Supplement 1].

Figure 2

Effect of SL1GRL on histamine-induced bronchoconstriction

In animals pretreated with propranolol (1 mg/kg i.v, 15 min), the response to histamine was increased compared to the pretreatment values [Figure 3 and Supplement 1]. However, propranolol did not abolish the inhibitory effect of SLIGRL on histamine-induced bronchoconstriction.

Figure 3

Effect of propranolol on bronchoprotection induced by SLIGRL

In vagotomized guinea pigs, the protective effect of SLIGRL against histamine-induced bronchoconstriction was still present [Figure 4 and Supplement 1].

Figure 4

Effect of vagotomy on bronchoprotection induced by SLIGRL

In animals pretreated with indomethacin (5 mg/kg i.p, 30 min), the response to histamine was increased compared to the pretreatment values [Figure 5 and Supplement 1].

Figure 5

Effect of indomethacin on bronchoprotection induced by SLIGRL

However, indomethacin failed to antagonize the inhibitory response of SLIGRL on the histamine-induced increase in airway resistance. Pretreatment with L­NAME (30 mg/kg i.v, 15 min) did not significantly change the response to histamine compared to the pretreatment values [Figure 6 and Supplement 1].

Figure 6

Effect of L-NAME on bronchoprotection induced by SLIGRL

Similarly, in animals pretreated with glibenclamide (30 mg/kg i.v, 35 min), the response to histamine was changed compared to the pretreatment values although this effect did not reach the level of statistical significance [Figure 7 and Supplement 1]. Animals, pretreated with either L-NAME or glibenclamide, did not show significant changes in the airway resistance compared to those induced by SLIGRL at 5 min and 10 min. However, the inhibitory effect of SLIGRL was prolonged by pretreatment with propranolol, vagotomy, and indomethacin.

Figure 7

Effect of glibenclamide on bronchoprotection induced by SLIGRL

Effect of SLIGRL on isolated tracheal strips in vitro

Effect of SLIGRL on acetylcholine, potassium chloride, and histamine-induced contractions of isolated guinea pigs tracheal strips

SLIGRL had no effect on the contractile response to ACh (4 μg/ml) and KCl (0.2 mg/ml), while it decreased the histamine-induced contraction [Figure 8].

Figure 8

Effect of (SLIGRL) on acetylcholine, potassium chloride and histamine-induced contraction of isolated guinea pig tracheal strips

Effect of SLIGRL on histamine-induced contractions of isolated guinea pig tracheal strips

SLIGRL produced a significant reduction in histamine­induced contraction by 11.2%, 21.6%, and 42% at concentrations of 1 μM, 5 μM, and 10 μM, respectively [Table 1, Figure 9 and Supplement 2].

Table 1

Effect of SLIGR on histamine-induced contraction of isolated guinea pig tracheal strips

Drug concentration	Histamine- induced contraction (cm)	Change (%)
Histamine (4 g/ml)	3.7±0.5
SLIGRL (1M)	3.3±0.6	-11.2 ± 4.2
SLIGRL (5 µM)	2.9±0.4*	-21.6 ± 0.2
SLIGRL (10 µM)	2.2±0.9*	-42 ± 16.6

Data represent the mean±SD of contraction and mean percent reduction of histamine-induced contraction. *P<0.05 versus the control (n=5). SD: Standard deviation

Figure 9

Effect of different doses of SLIGRL on histamine-induced contraction contraction of isolated guinea pig tracheal strips

Supplement 2

Effect of propranolol, vagotomy, indomethacin, L-NAME and glibencalamide on bronchoprotection induced by PAR-2-AP

	Baseline (cm)	Control (histamine) (10 µg/kg)	LSIG (l mg/kg)	SLIGRL (l mg/kg)	Propranolol (l mg/kg)	Vagotomy	Indomethacin (5 mg/kg)	L-NAME (30 mg/kg)	Glibenclamide (30 mg/kg)
Change in airway resistance from baseline (%)	4.06±0.48	6.l0±0.69 (cm) +33.49% ±2.25
Change in airway resistance after drug administration compared to control (%)					+20.48±2.99	+11.80±l. 82	+25.82±8.08	+7.55±0.29	+9.94±1.79
Percentage decrease from 1 control min			−3.99*±0.91	−43.94±1.12	−39.83*±8.04	−38.27*±2.22	−34.41*±4.72	−40.24*±2.2	−36.67*±l. 44
Percentage of airway resistance relative to control			96.01	56.06	60.17	61.73	65.59	59.76	63.33
Percentage decrease from 5 control min			−2.99*±0.04	−28.55±3.04	−21.04*±1.12	−26.57±5.20	−25*±1.27	−27.7±1.54	−26.63±4.45
Percentage of airway resistance relative to control			97.01	71.45	75.88	73.43	75	72.3	73.37
Percentage decrease from 10 control mm			−1.49*±0.02	−5.23±l. 60	−7.42*±0.41	−7.36*±0.22	−8.37*±1.94	−6.27±0.87	−6.65±1.53
Percentage of airway resistance relative to control			98.5	94.77	92.58	92.64	91.63	93.73	93.35

Data represent mean±SD of percentage change of airway resistance. *Significant compared to the corresponding SLIGRL value P<0.05. Response to histamine (control) was evaluated 1, 5 and 10 min after SLIGRL administration. SD: Standard deviation

DISCUSSION

In the present study, we demonstrated the bronchodilator effect of PAR-2-AP (SLIGRL) against histamine-induced bronchospasm both in vivo and in isolated tissue preparations in vitro. Intravenous injection of SLIGRL produced a significant reduction in airway resistance induced by histamine in anesthetized guinea pigs. In addition, SLIGRL produced a dose-dependent reduction in histamine-induced contractions of isolated guinea pig tracheal strips. These findings are consistent with those reported by Cicala et al.[22] showing that SLIGRL protected against histamine-induced bronchoconstriction in a guinea pig model. Furthermore, Kawabata et al.[29] reported that SLIGRL-NH2 elicited tracheal relaxation. In contrast to the findings of the present study, Barrios et al.[30] reported that SLIGRL treatment increased the responsiveness to histamine in isolated guinea pig bronchi. Furthermore, Chambers et al.[31] demonstrated that PAR-2 activation induced human airway contraction and potentiated the effects of histamine, which may contribute to airway diseases such as asthma. Similarly, Schmidlin et al.[32] reported that PAR-2 activation mobilized intracellular calcium and increased human bronchial smooth muscles contraction. In 2002, Schmidlin et al.[33] used a mouse model of allergic airway inflammation to show that PAR-2 deletion reduced airway hyperresponsiveness, while PAR-2 overexpression had the opposite effect. Thus, these discrepancies suggest that PAR-2 activation can occur through different pathways.

The mechanism of the observed SLIGRL-induced bronchodilation is still not clear; therefore, in the present study, we investigated the role of indirect mechanisms underlying bronchoprotection, including the release of prostaglandins E2 (PGE2), nitric oxide (NO), activation of β-adrenergic receptors, and opening of ATP-sensitive K + channels. We used cyclooxygenase (COX) and NO synthase (NOS) inhibitors, β-adrenergic receptor antagonists, ATP-sensitive K + channel blockers, and vagotomy to investigate each of these pathways. Our results demonstrate the noncholinergic, nonadrenergic bronchodilator effects of SLIGRL in vitro. SLIGRL failed to antagonize ACh-induced contraction and the β-adrenoceptor blocker, propranolol, failed to antagonize the relaxant effect of SLIGRL on histamine-induced contraction. Moreover, vagotomy did not abolish the relaxant effect of SLIGRL. These results are in contrast to those reported by Ricciardolo et al.[20] showing that SLIGRL-NH2(0.1–10 μM) caused a concentration-dependent relaxation of isolated tracheal rings precontracted with carbachol (1 µM). Similarly, Lan et al. and De Campo and Henry reported that a PAR-2-AP has been shown to inhibit methacholine-induced bronchoconstriction in mice.[1834]

Our data showed that intravenous administration of PAR-2-AP to guinea pigs inhibits the histamine-induced increase in the lung resistance through a mechanism independent of the release of prostaglandin and NO. Furthermore, this effect was not dependent on either circulating adrenaline or opening of ATP-sensitive K + channels. These findings are consistent with the report by Cicala et al.[22] that intravenous administration of PAR-2-AP to guinea pigs inhibited the histamine-induced increase in the lung resistance through a mechanism that was independent of the release of prostaglandin, NO, and the effects of circulating adrenaline.

Cocks et al.[17] proposed that the protective effect of PAR-2-AP on airway reactivity in vitro is dependent on the involvement of epithelial PGE2. The discrepancy between the in vivo data obtained in the present study and those obtained by others using in vitro airway preparations is likely to be due to the complex interactions present in an in vivo setting. A similar discrepancy between data obtained in vitro and in vivo has also been observed for hemodynamic changes mediated by PAR-2 activation.[22] In contrast to our findings, Emilsson et al.[35] and Moffatt and Cocks[36] showed that PAR-2-AP-induced relaxation of isolated vascular tissues through a mechanism that was clearly dependent upon NO release from endothelial cells in vitro.

In the present study, indomethacin treatment significantly augmented the histamine-induced increase in baseline resistance. The mechanism by which indomethacin induces an increase in airway responsiveness to histamine is still uncertain but is known to be dependent on vagal reflex pathways[3738] and also to the inhibition of airway-derived PGE2, which is known to have a bronchoprotective effect.[394041]

Morello et al.[19] found that PGE2 release by tissues was significantly increased following incubation with PAR-2-AP. In contrast to the present study, the bronchorelaxant effect of PAR-2-AP was inhibited by ibuprofen. In addition, a selective COX-2 inhibitor blocked the bronchorelaxant effect of PAR-2-AP, suggesting strongly that COX-2-derived PGE2 is involved in this effect. Furthermore, PGE2 synthesis by gastrointestinal myofibroblasts is induced by PAR-2 activation.[42]

In contrast to the present study, Lan et al.[18] demonstrated that the upregulation of PARs in the airways is coupled to increased COX activation and enhanced generation of bronchodilatory prostanoids. Similarly, Kawabata et al.[29] found that PAR-2-mediated relaxation in mouse tracheal and bronchial smooth muscle through a mechanism involving both COX-1 and COX-2. Kawao et al.[43] also showed that the PAR-2-AP SLIGRL increased PGE2 synthesis in human A549 alveolar epithelial cells through a mechanism that involved COX-2 upregulation.

L-NAME failed to reverse the bronchoprotection observed with SLIGRL, indicating that the bronchoprotective effect of SLIGRL is unlikely to be due to the release of NO. In accordance with our findings, Chow et al.[44] reported that the SLIGRL-induced airway relaxation was unaffected by L-NAME. In contrast, Cicala et al.[45] found that PAR-2 modulates vascular reactivity both in vitro and in vivo and that PAR-2-AP-induced vasorelaxation is modulated by basal NO. In contrast to the present study, Ricciardolo et al.[20] showed that injection of SLIGRL-NH2 caused a significant increase in airway resistance (increased bronchoconstriction). This effect was significantly increased by pretreatment with a NOS inhibitor, while indomethacin pretreatment caused a significant decrease in the effect of SLIGRL-NH2. Robin et al.[46] reported that PAR-2-mediated vasodilatation in humans in vivo was reduced by both NO and prostanoids, while Risse et al.[47] reported that PAR-2 activation in guinea pigs induced smooth muscle relaxation through epithelial release of prostanoids but not NO.

Relaxation of human isolated airway smooth muscle is mediated through activation of K + channels on the airway epithelium.[48] ATP­sensitive K + channel activators may inhibit airway smooth contraction induced by chemical mediators.[49] McGuire et al.[50] also reported that glibenclamide and propranolol did not inhibit relaxation induced by SLIGRL in mouse mesenteric arterioles, whereas relaxation was partially reduced by L-NAME and indomethacin. They demonstrated that glibenclamide did not inhibit relaxation induced by PAR-2, whereas relaxation was inhibited by apamin/charybdotoxin, suggesting that endothelium-dependent hyperpolarization involves the activation of apamin/charybdotoxin-sensitive K + channels not ATP-sensitive K + channels.

In the present study, SLIGRL failed to inhibit KCl-induced contraction of isolated tracheal spiral strips. The findings of the present work were consistent with those of McGuire et al.[51] who demonstrated that the effects of the SLIGRL on membrane potential and tension were not observed in the blood vessels that were contracted with KCl. On the other hand, McGuire et al. found that PAR-2-induced relaxation was inhibited by KCl precontraction.

CONCLUSION

We have demonstrated the protective role of PAR-2 activation against histamine-induced contraction in the guinea pig airways in vivo; however, it appears that PAR-2-AP mediates this effect independently of prostanoids, NO, and circulating adrenaline. In vitro studies showed that SLIGRL did not affect the tracheal contraction induced by ACh and KCl but inhibited histamine-induced contraction in a dose-dependent manner. Furthermore, the effects of PAR-2 are species specific, thus demonstrating the necessity of clinical trials to evaluate the effects of PAR-2-AP in humans.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Effect of SLIGRL on airway resistance in anesthetized guinea pigs. The response to histamine was evaluated 1, 5, and 10 min after SLIGRL administration